Financial Comparison: BioScrip (BIOS) & The Competition
BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it compare to its rivals? We will compare BioScrip to similar businesses based on the strength of its risk, analyst recommendations, valuation, institutional ownership, dividends, earnings and profitability.
Insider & Institutional Ownership
84.7% of BioScrip shares are held by institutional investors. Comparatively, 69.6% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by institutional investors. 0.8% of BioScrip shares are held by company insiders. Comparatively, 10.4% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares BioScrip and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
BioScrip has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s rivals have a beta of 1.47, meaning that their average stock price is 47% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for BioScrip and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
BioScrip currently has a consensus price target of $3.75, suggesting a potential upside of 44.79%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 22.94%. Given BioScrip’s stronger consensus rating and higher possible upside, analysts plainly believe BioScrip is more favorable than its rivals.
Valuation and Earnings
This table compares BioScrip and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|BioScrip||$935.59 million||-$41.50 million||-4.18|
|BioScrip Competitors||$1.06 billion||-$22.56 million||738.92|
BioScrip’s rivals have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
BioScrip rivals beat BioScrip on 8 of the 12 factors compared.
BioScrip Company Profile
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related companies with MarketBeat.com's FREE daily email newsletter.